Analyst firms · Barclays · LLY

Barclays LLY price target and rating history

Eli Lilly and Company (LLY) · Health Care

Barclays rates Eli Lilly and Company (LLY) Overweight with a $1,350 price target, as of its latest action on Feb 20, 2026. It has published 3 rating actions on LLY since July 2021, including 0 upgrades and 0 downgrades. Across 10 firms with a LLY price target in the last 12 months, the median target is $1,240. Barclays's $1,350 is 9% above that.

Current rating
Overweight
Price target
$1,350
Median target, all firms
$1,240
Actions on LLY
3

Barclays price target on LLY

$1,350$800$25020222023202420252026
Barclays price target on LLY, each point a stated target, July 2021 to February 2026.

Every Barclays rating on LLY

How other firms rate LLY

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BerenbergBuy$1,400Sep 15, 2026
HSBCReduce$850Mar 17, 2026
RBC Capital MarketsOutperform$1,250Feb 25, 2026
BarclaysOverweight$1,350Feb 20, 2026
UBSBuy$1,250Jan 7, 2026
DaiwaBuy$1,230Dec 16, 2025
Goldman SachsBuy$1,145Dec 15, 2025
BofA SecuritiesBuy$1,268Dec 15, 2025
ScotiabankSector Outperform$1,165Nov 13, 2025
Leerink PartnersOutperform$1,104Nov 10, 2025

Questions about Barclays and LLY

What is Barclays's price target for LLY?
Barclays's latest stated price target for Eli Lilly and Company (LLY) is $1,350, from its action on Feb 20, 2026.
What is Barclays's rating on LLY?
Barclays rates LLY Overweight, a bullish rating, as of Feb 20, 2026.
When did Barclays last change its view on LLY?
On Feb 20, 2026, Barclays starts coverage at Overweight, price target $1,350.
How does Barclays's LLY target compare with other analysts?
Across 10 firms with a LLY price target in the last 12 months, the median target is $1,240. Barclays's $1,350 is 9% above that.

More LLY rating histories

All Barclays ratingsLLY news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.